Lung Cancer
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global lung cancer drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 13–24 of 24 articles
Osimertinib FDA Approval Expands Early-Stage NSCLC Treatment
Summit Therapeutics Ivonescimab Shows Overall Survival Benefit in Lung Cancer, ASCO 2026 Plenary Data Expected
KRAS G12C Inhibitors NSCLC: Market Analysis of Sotorasib & Adagrasib
FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
ASCO 2026: Top Oncology Trials to Watch
FDA Approval KRAS G12C NSCLC: Sotorasib & Adagrasib Insights
FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib
Pfizer Presents LORBRENA and BRAFTOVI Cancer Trial Updates at ASCO 2026
Revolution Medicines Presents Updated Zoldonrasib Phase 1 Data for KRAS G12D Lung Cancer at AACR 2026
Boehringer Ingelheim's Zongertinib Shows Promise for HER2-Mutant Lung Cancer in NEJM Study
FDA Approves Tecentriq for Extensive-Stage Small Cell Lung Cancer
FDA Grants Priority Review to Sotorasib for KRAS G12C NSCLC